Dry Powder: Live from SuperReturn 2024

Dry Powder: Live from SuperReturn 2024

Up next

The Infrastructure Opportunities Hiding in Plain Sight w/ NOVA Infrastructure’s Allison Kingsley and Chris Beall

We ask the co-founders of NOVA Infrastructure about the investment opportunities flying beneath the radar of large infrastructure investors, and the value that can be created by professionalizing smaller businesses. 

Building the New Economy w/ Ares' Kipp deVeer

In part two of our interview series, Ares Co-President Kipp deVeer explains where the firm sees the strongest opportunities in the “new economy," and why it’s moving from financing data centers to building them. 

Recommended Episodes

Periodical table
Grant's Current Yield Podcast

Porter Stansberry, founder and editor of Stansberry Research, joins Jim for an enlivening conversation about the business and financial world at large. 

1:33 What do people want to do with their money?

5:08 1999 and today

8:01 The #bitcoin pitch

12: ...

  Show more

The Deal Room: Blackstone takes the hit on Bumble - why PE is taking a loss on its listed portfolio
Market Maker

Welcome to a brand new series coming at you every Wednesday where I'm joined by Stephen Barnett our Director of Corporate Finance at AmplifyME.


The objective of 'The Deal Room' is to complement our end-of-week chat about global markets with a more M&A and Private ...

  Show more

The Future of Private Equity Fundraising with Brian Bank from Kirkland and Ellis
Private Equity Podcast: Karma School of Business

Join host Sean Mooney and Brian Bank, a seasoned strategy and client relations executive from Kirkland & Ellis, for an enlightening discussion on the private equity landscape. With over 25 years of experience as both an institutional limited partner and placement agent, Brian del ...  Show more

Leading with science: A deep dive on biotech
Center For Investment Excellence

In this episode, David Lebovitz, Global Strategist, Multi-Asset Solutions, is joined by Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital, to discuss the alternative investment landscape, the private biotech market and areas of opportunity in 20 ...  Show more